Humabs Biomed Sa

Medimmune Limited

Institute for Research in Biomedicine

National Institutes of Health, a Component of the US Dept. of Health & Human Services

Institut Pasteur

Vir Biotechnology, Inc.

US Government As Represented by the Secretary of the Army

Other

The Pirbright Institute

Davide Corti

Antonio Lanzavecchia

Baoshan Zhang

Nicole Kallewaard-LeLay

Qing Zhu

Andy Q Yuan

Josephine Mary McAuliffe

Leslie Wachter

Ebony Benjamin

Guillaume Stewart-Jones

Yongping Yang

Elisabetta Cameroni

Martina Beltramello

Peter D Kwong

Anna DeMarco

Peter L Collins

Ursula J Buchholz

Michael Gordon Joyce

Charles K Stover

Bret Sellman

Xiaodong Xiao

Christine Tkaczyk

Qun Wang

Andrea Minola

Meghan Pennini

Gilad Kaplan

Gwo-Yu Chuang

Wing-Pui Kong

Aliaksandr Druz

Yaroslav Tsybovsky

Li Ou

Kai Xu

Frances Palmer-Hill

Barbara Guarino

Hervé Bourhy

John R Mascola

Barney S Graham

Tongqing Zhou

Melissa Marie Damschroder

Nancy J Sullivan

Gyorgy Pal Snell

Qun Du

Julie Ledgerwood

Martin Borrok, Iii

Chew-shun Chang

Paul Thomas

Jamese Johnson Hilliard

Florian A Lempp

Amalio Telenti

Sabue Mulangu

Jean-Jacques Muyembe-Tamfun

John Trefry

Katja Fink

Lei Chen

Wing-pui Kong

Dora Pinto

Luca Piccoli

Daphne Stanley

William J Rutter

John Mascola

Fabio Grassi

Anna Bakardjiev

Fabio Benigni

Matteo Samuele Pizzuto

Phillip S Pang

Geraldine Taylor

Lisa Perruzza

Jean Christophe Sabue Mulangu

Barncy Graham

Embodiments of a recombinant human Parainfluenza Virus (hPIV) F ectodomain trimer stabilized in a prefusion conformation are provided. Also disclosed are nucleic acids encoding the hPIV F ectodomain trimer and methods of producing the hPIV F ectodomain trimer. Methods for inducing an immune response in a subject are also disclosed. In some embodiments, the method can be a method for treating or inhibiting a hPIV infection in a subject by administering a effective amount of the recombinant hPIV F ectodomain trimer to the subject.

Prefusion PIV F immunogens and their use

The present disclosure provides methods for treating HBV infection using combination therapies, and related kits and compositions for use. The components of the combination therapies include an inhibitor of HBV gene expression or an agent that reduces HBV antigenic load, and an anti-HBV antibody.

Combination HBV therapy

The invention relates to antibodies and antigen binding fragments thereof that are capable of binding to influenza B virus hemagglutinin (HA) and neutralizing influenza B virus in two phylogenetically distinct lineages. In one embodiment, the antibody or antigen binding fragment is capable of binding to influenza B virus hemagglutinin and neutralizing influenza B virus in Yamagata and Victoria lineages.

Neutralizing anti-influenza B antibodies and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind to02 and induce opsonophagocytic killing of Klebsiella (e.g., Klebsiellapneumoniae) and/or protects mice from a lethalchallenge. The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering thepneumoniae 02 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O2 antibodies and uses thereof

The present disclosure relates to antibodies, and antigen binding fragments thereof, that can bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and can neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The present disclosure also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to fusion proteins that comprise the antigen binding fragments, and to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the present disclosure relates to the use of the antibodies and antibody fragments of the present disclosure in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

Antibodies that neutralize hepatitis B virus and uses thereof

The instant disclosure provides antibodies and antigen-binding fragments thereof that are specific forand, in certain embodiments, are capable of neutralizing ainfection in a subject. In certain embodiments, the antibody or antigen binding fragment comprises an IgA antibody, such as, for example, a secretory IgA antibody. Also provided are pharmaceutical compositions comprising a disclosed antibody or antigen-binding fragment. Methods of using the antibodies, antigen-binding fragments, and compositions to treat or prevent ainfection in a subject are also provided. In certain embodiments, recombinant secretory IgA antibodies of the instant disclosure are administered orally to a subject having or at risk of developing ainfection.

Antibodies againstspecies

Metapneumovirus (MPV) F proteins stabilized in a prefusion conformation, nucleic acid molecules and vectors encoding these proteins, and methods of their use and production are disclosed. In several embodiments, the MPV F proteins and/or nucleic acid molecules can be used to generate an immune response to MPV in a subject. In additional embodiments, the therapeutically effective amount of the MPV F ectodomain trimers and/or nucleic acid molecules can be administered to a subject in a method of treating or preventing MPV infection.

Recombinant metapneumovirus f proteins and their use

The present invention relates to antibodies, and antigen binding fragments thereof, that bind to the antigenic loop region of hepatitis B surface antigen (HBsAg) and potently neutralize infection of both hepatitis B virus (HBV) and hepatitis delta virus (HDV). The invention also relates to epitopes to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in the diagnosis, prophylaxis and treatment of hepatitis B and hepatitis D.

Antibodies that potently neutralize hepatitis B virus and uses thereof

The present disclosure provides binding proteins (e.g., antibodies or antigen binding fragments thereof) that specifically bind toO1 and induce opsonophagocytic killing of(e.g.,). The present disclosure also provides methods of reducing(e.g.,) or treating or preventing(e.g.,) infection in a subject comprising administering theO1 binding proteins, (e.g., antibodies or antigen-binding fragments thereof) to the subject.

Anti-O1 antibodies and uses thereof

The present disclosure is directed to a monoclonal antibody, or antigen-binding fragment thereof, that specifically binds to aclumping factor A protein (ClfA), as well as compositions comprising the monoclonal antibody. The disclosure also is directed to methods of treating ainfection by administering the anti-ClfA monoclonal antibody alone, or in combination with a monoclonal antibody that specifically binds toalpha toxin (AT) protein to a subject. Bispecific monoclonal antibodies that specifically bind to both ClfA and AT and methods of using the same also are provided.

Antibody directed againstclumping factor A (ClfA)

The invention relates to antibodies and binding fragments thereof that are capable of binding to influenza A virus hemagglutinin and neutralizing at least one group 1 subtype and at least 1 group 2 subtype of influenza A virus.

Neutralizing anti-influenza A antibodies and uses thereof

The invention relates to multispecific antibodies, and antigen binding fragments thereof, that specifically bind to distinct Zika virus epitopes and potently neutralize infection of ZIKV. The invention also relates to nucleic acids that encode such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in prophylaxis and treatment of ZIKV infection.

Multispecific antibodies specifically binding to Zika virus epitopes

The invention relates to antibodies, and antigen binding fragments thereof, that potently neutralize infection of ZIKV. The invention also relates to antigenic sites to which the antibodies and antigen binding fragments bind, as well as to nucleic acids that encode and immortalized B cells that produce such antibodies and antibody fragments. In addition, the invention relates to the use of the antibodies and antibody fragments of the invention in screening methods as well as in the diagnosis, prophylaxis and treatment of ZIKV infection.

Antibodies specifically binding to Zika virus epitopes and uses thereof

Neutralizing anti-influenza b antibodies and uses thereof

Growing community of inventors

Bellinzona, Switzerland

Davide Corti